

## [Artemether](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines](#) > [Medicines for curative treatment](#)

ATC codes: [P01BE02](#)

EMLc

Indication

Malaria due to Plasmodium vivax ICD11 code: [1F81](#)

INN

Artemether

Medicine type

Chemical agent

List type

Core

Additional notes

For use in the management of severe malaria

Formulations

**Parenteral > General injections > IM:** 20 mg per mL in 1 mL ampoule (oily injection) ; 40 mg per mL in 1 mL ampoule (oily injection)

EML status history

First added in 1997 ([TRS 882](#))

Changed in 2002 ([TRS 914](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Artemether](#)

DrugBank

[Artemether](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended replacing the 80 mg/mL strength of artemether oily injection with 20 mg/mL and 40 mg/mL strengths. The 80 mg/mL strength has limited utility for children under 12 years of age.